Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz JS.

Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918.

2.

Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Freudenmann LK, Marcu A, Stevanović S.

Immunology. 2018 Jul;154(3):331-345. doi: 10.1111/imm.12936. Epub 2018 May 8. Review.

3.

Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.

Kowalewski DJ, Walz S, Backert L, Schuster H, Kohlbacher O, Weisel K, Rittig SM, Kanz L, Salih HR, Rammensee HG, Stevanović S, Stickel JS.

Blood Cancer J. 2016 Apr 8;6:e411. doi: 10.1038/bcj.2016.14.

4.
5.

HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).

Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. doi: 10.1073/pnas.1416389112. Epub 2014 Dec 29. Erratum in: Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6254-6. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6258-60.

6.

Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanović S, Stickel JS.

Leukemia. 2015 Mar;29(3):647-59. doi: 10.1038/leu.2014.233. Epub 2014 Aug 5. Erratum in: Leukemia. 2016 Apr;30(4):1003-4.

PMID:
25092142
7.

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O'Reilly RJ.

Blood. 2012 Aug 23;120(8):1633-46. doi: 10.1182/blood-2011-11-394619. Epub 2012 May 23.

8.

Expression of epithelial cancer-related antigens in hematologic malignancies applicable for peptide-based immunotherapy.

Takedatsu H, Okamura T, Yoshimoto K, Harada M, Koga M, Shichijo S, Sata M, Itoh K.

J Immunother. 2004 Jul-Aug;27(4):289-97.

PMID:
15235390
9.

Antigen Targets for the Development of Immunotherapies in Leukemia.

Bauer J, Nelde A, Bilich T, Walz JS.

Int J Mol Sci. 2019 Mar 20;20(6). pii: E1397. doi: 10.3390/ijms20061397. Review.

10.

Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.

Klar R, Schober S, Rami M, Mall S, Merl J, Hauck SM, Ueffing M, Admon A, Slotta-Huspenina J, Schwaiger M, Stevanović S, Oostendorp RA, Busch DH, Peschel C, Krackhardt AM.

Leukemia. 2014 Dec;28(12):2355-66. doi: 10.1038/leu.2014.131. Epub 2014 Apr 16.

PMID:
24736212
11.

The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.

Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Freudenmann LK, Peper JK, Marcu A, Wang SS, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanović S, Weller M, Eisele G.

Acta Neuropathol. 2018 Jun;135(6):923-938. doi: 10.1007/s00401-018-1836-9. Epub 2018 Mar 20.

PMID:
29557506
12.

A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.

Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G.

Clin Cancer Res. 2013 Jan 1;19(1):247-57. doi: 10.1158/1078-0432.CCR-12-2753. Epub 2012 Nov 12.

13.

Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.

Hee Lee J, Park MS, Hwang JE, Cho SH, Bae WK, Shim HJ, Kim DE, Chung IJ.

Cell Mol Immunol. 2013 May;10(3):275-82. doi: 10.1038/cmi.2012.74. Epub 2013 Mar 25.

14.

Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.

Matsushita M, Yamazaki R, Ikeda H, Kawakami Y.

Leuk Lymphoma. 2003 Mar;44(3):439-44. Review.

PMID:
12688312
15.

Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.

Siegel S, Wagner A, Kabelitz D, Marget M, Coggin J Jr, Barsoum A, Rohrer J, Schmitz N, Zeis M.

Blood. 2003 Dec 15;102(13):4416-23. Epub 2003 Jul 17.

16.

Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients.

Meier A, Reker S, Svane IM, Holten-Andersen L, Becker JC, Søndergaard I, Andersen MH, Thor Straten P.

Cancer Immunol Immunother. 2005 Mar;54(3):219-28. Epub 2004 Oct 2.

PMID:
15580499
17.

Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.

Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P, Ritter G, Wiesneth M, Döhner H, Schmitt M.

Blood. 2005 Aug 1;106(3):938-45. Epub 2005 Apr 12.

18.

High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.

Jarmalavicius S, Welte Y, Walden P.

J Biol Chem. 2012 Sep 28;287(40):33401-11. Epub 2012 Aug 6.

19.

Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles.

Bachinsky MM, Guillen DE, Patel SR, Singleton J, Chen C, Soltis DA, Tussey LG.

Cancer Immun. 2005 Mar 22;5:6.

20.

Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.

Han JF, Zhao TT, Liu HL, Lin ZH, Wang HM, Ruan ZH, Zou LY, Wu YZ.

Cancer Immunol Immunother. 2006 Dec;55(12):1575-83. Epub 2006 Mar 14.

PMID:
16534571

Supplemental Content

Support Center